{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:53:14Z","timestamp":1665190394224},"reference-count":28,"publisher":"The Society for Free Radical Research Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Biochem. Nutr."],"published-print":{"date-parts":[[2020]]},"DOI":"10.3164\/jcbn.20-88","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T22:07:51Z","timestamp":1601417271000},"page":"274-282","source":"Crossref","is-referenced-by-count":2,"title":["Trans-portal hepatic infusion of cultured bone marrow-derived mesenchymal stem cells in a steatohepatitis murine model"],"prefix":"10.3164","volume":"67","author":[{"given":"Ryo","family":"Sasaki","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Takami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine"},{"name":"Center for Regenerative and Cell Therapy, Yamaguchi University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Liver Regenerative Medicine, Yamaguchi University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Yamaguchi University Health Administration Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Sakaida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine"},{"name":"Center for Regenerative and Cell Therapy, Yamaguchi University Graduate School of Medicine"},{"name":"Department of Liver Regenerative Medicine, Yamaguchi University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1739","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Sakaida I, Terai S, Yamamoto N, et al. Transplantation of bone marrow cells reduces CCl<sub>4<\/sub>-induced liver fibrosis in mice. Hepatology 2004; 40: 1304\u20131311.","DOI":"10.1002\/hep.20452"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Terai S, Ishikawa T, Omori K, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 2006; 24: 2292\u20132298.","DOI":"10.1634\/stemcells.2005-0542"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Iwamoto T, Terai S, Mizunaga Y, et al. Splenectomy enhances the anti-fibrotic effect of bone marrow cell infusion and improves liver function in cirrhotic mice and patients. J Gastroenterol 2012; 47: 300\u2013312.","DOI":"10.1007\/s00535-011-0486-7"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Tanimoto H, Terai S, Taro T, et al. Improvement of liver fibrosis by infusion of cultured cells derived from human bone marrow. Cell Tissue Res 2013; 354: 717\u2013728.","DOI":"10.1007\/s00441-013-1727-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Matsuda T, Takami T, Sasaki R, et al. A canine liver fibrosis model to develop a therapy for liver cirrhosis using cultured bone marrow-derived cells. Hepatol Commun 2017; 1: 691\u2013703.","DOI":"10.1002\/hep4.1071"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Nishimura T, Takami T, Sasaki R, et al. Liver regeneration therapy through the hepatic artery-infusion of cultured bone marrow cells in a canine liver fibrosis model. PLoS One 2019; 14: e0210588.","DOI":"10.1371\/journal.pone.0210588"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Lade A, Noon LA, Friedman SL. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol 2014; 26: 100\u2013107.","DOI":"10.1097\/CCO.0000000000000042"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int 2017; 37 Suppl 1: 81\u201384.","DOI":"10.1111\/liv.13299"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Ekstedt M, Hagstr\u00f6m H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547\u20131554.","DOI":"10.1002\/hep.27368"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 389\u2013397.","DOI":"10.1053\/j.gastro.2015.04.043"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017; 65: 1557\u20131565.","DOI":"10.1002\/hep.29085"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Komiya C, Tanaka M, Tsuchiya K, et al. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Sci Rep 2017; 7: 44754.","DOI":"10.1038\/srep44754"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Fujisawa K, Hara K, Takami T, et al. Evaluation of the effects of ascorbic acid on metabolism of human mesenchymal stem cells. Stem Cell Res Ther 2018; 9: 93.","DOI":"10.1186\/s13287-018-0825-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Winkler S, Borkham-Kamphorst E, Stock P, et al. Human mesenchymal stem cells towards non-alcoholic steatohepatitis in an immunodeficient mouse model. Exp Cell Res 2014; 326: 230\u2013239.","DOI":"10.1016\/j.yexcr.2014.04.017"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Lee CW, Hsiao WT, Lee OKS. Mesenchymal stromal cell-based therapies reduce obesity and metabolic syndromes induced by a high-fat diet. Transl Res 2017; 182: 61\u201374.e8.","DOI":"10.1016\/j.trsl.2016.11.003"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Cao M, Pan Q, Dong H, et al. Adipose-derived mesenchymal stem cells improve glucose homeostasis in high-fat diet-induced obese mice. Stem Cel Res Ther 2015; 6: 208.","DOI":"10.1186\/s13287-015-0201-3"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Banas A, Teratani T, Yamamoto Y, et al. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology 2007; 46: 219\u2013228.","DOI":"10.1002\/hep.21704"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Itoh M, Suganami T, Kato H, et al. CD11c<sup>+<\/sup> resident macrophages drive hepatocyte death-triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis. JCI Insight 2017; 2: e92902.","DOI":"10.1172\/jci.insight.92902"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Nakashima H, Nakashima M, Kinoshita M, et al. Activation and increase of radio-sensitive CD11b<sup>+<\/sup> recruited Kupffer cells\/macrophages in diet-induced steatohepatitis in FGF5 deficient mice. Sci Rep 2016; 6: 34466.","DOI":"10.1038\/srep34466"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Krenkel O, Puengel T, Govaere O, et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology 2018; 67: 1270\u20131283.","DOI":"10.1002\/hep.29544"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Wan J, Benkdane M, Teixeira-Clerc F, et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 2014; 59: 130\u2013142.","DOI":"10.1002\/hep.26607"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Baeck C, Wehr A, Karlmark KR, et al. Pharmacological inhibition of the chemokine CCL2(MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 2012; 61: 416\u2013426.","DOI":"10.1136\/gutjnl-2011-300304"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Zhou YZ, Cheng Z, Wu Y, et al. Mesenchymal stem cell-derived conditioned medium attenuate angiotensin \u2161-induced aortic aneurysm growth by modulating macrophage polarization. J Cell Mol Med 2019; 23: 8233\u20138245.","DOI":"10.1111\/jcmm.14694"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Cho DI, Kim MR, Jeong HY, et al. Mesenchymal stem cells reciprocally regulate the M1\/M2 balance in mouse bone marrow-derived macrophages. Exp Mol Med 2014; 46: e70.","DOI":"10.1038\/emm.2013.135"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Calvente CJ, Tameda M, Johnson CD, et al. Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223. J Clin Invest 2019; 130: 4091\u20134109.","DOI":"10.1172\/JCI122258"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Griess B, Mir S, Datta K, Teoh-Fitzgerald M. Scavenging reactive oxygen species selectively inhibits M2 macrophage polarization and their pro-tumorigenic function in part, via Stat 3 suppression. Free Radic Biol Med 2020; 147: 48\u201360.","DOI":"10.1016\/j.freeradbiomed.2019.12.018"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Sha W, da Costa KA, Fischer LM, et al. Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline. FASEB J 2010; 24: 2962\u20132975.","DOI":"10.1096\/fj.09-154054"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Mascar\u00f3 C, Acosta E, Ortiz JA, Marrero PF, Hegardt FG, Haro D. Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. J Biol Chem 1998; 273: 8560\u20138563.","DOI":"10.1074\/jbc.273.15.8560"}],"container-title":["Journal of Clinical Biochemistry and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/67\/3\/67_20-88\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T03:53:13Z","timestamp":1604721193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/67\/3\/67_20-88\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.3164\/jcbn.20-88","relation":{},"ISSN":["0912-0009","1880-5086"],"issn-type":[{"value":"0912-0009","type":"print"},{"value":"1880-5086","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}